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Objective: The objective of this study was to describe the outcomes of surgical revascularization for lower extremity arterial
thromboembolism in patients with advanced malignancy.
Methods: The 2005-2011 American College of Surgeons National Surgical Quality Improvement Program database was
used for this study. Preoperative characteristics and postoperative outcomes of patients with known advanced ma-
lignancy who underwent surgical revascularization for lower extremity arterial thromboembolic disease were assessed
and compared with those of patients without known advanced malignancy. Parsimonious multivariate logistic
regression analysis was used to determine the independent association between advanced malignancy and 30-day
postoperative mortality and morbidity after adjustment for demographic characteristics, acute and chronic comor-
bid disease burden, history of peripheral arterial disease, functional and nutritional status, acuity of presentation, and
procedure type.
Results: The study included 136 patients with advanced malignancy who underwent surgical revascularization for lower
extremity arterial thromboembolism for analysis (65% thromboembolectomy, 26% thromboendarterectomy, and 22%
bypass grafting). The 30-day mortality and morbidity rates in these patients were 30.2% and 38.2%, respectively.
Compared with patients without advanced malignancy, patients with advanced malignancy had a signiﬁcantly greater risk
of postoperative death (adjusted odds ratio, 5.92; 95% conﬁdence interval, 3.69-9.52; P < .001) but not morbidity
(adjusted odds ratio, 1.28; 95% conﬁdence interval, 0.87-1.87; P [ .21).
Conclusions: Our study is the largest to date to describe the outcomes of patients with advanced malignancy who undergo
surgical revascularization for arterial thromboembolism of the lower extremities. Such patients suffer high rates of early
postoperative mortality and morbidity, especially when emergency operation is required. Early involvement of palliative
care specialists is warranted in these patients to ensure that the decision to pursue surgical revascularization is aligned with
their goals of care. (J Vasc Surg 2014;60:987-92.)Arterial thromboembolism is an increasingly recog-
nized manifestation of malignancy.1-11 Several factors
can predispose cancer patients to arterial thromboembolic
disease, including pre-existing atherosclerotic burden, the
thrombophilic milieu associated with cancer, and
chemotherapy-mediated vascular endothelial dam-
age.3,10-12 Regardless of the underlying cause, the ques-
tion of how best to manage arterial ischemic events in
the setting of malignancy is difﬁcult, in part because there
is a paucity of evidence available in the literature with
which to inform surgeons and patients about the risks
and anticipated results of surgical intervention. For
example, only ﬁve studies with a combined sample size
of 44 patients have been published to date that describethe Department of Surgery, Duke University Medical Center.
or conﬂict of interest: none.
rint requests: Kyla M. Bennett, MD, Division of Vascular Surgery,
epartment of Surgery, DUMC 2833, Duke University Medical Center,
urham, NC 27710 (e-mail: benne051@mc.duke.edu).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2014 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2014.04.064outcomes associated with operation for critical lower
limb ischemia in patients with cancer.1,4,7-9 On the basis
of the conclusions from these studies, it remains unclear
which patients from this population should be treated
with aggressive surgical intervention rather than with
palliation.4-8
The American College of Surgeons National Surgical
Quality Improvement Program (ACS NSQIP) provides
a unique opportunity to improve our understanding
of the surgical outcomes for relatively uncommon con-
ditions such as cancer-associated arterial thromboem-
bolic disease. With its inclusion of approximately 1.3
million surgical procedures performed at more than
250 member hospitals, ACS NSQIP enables the anal-
ysis of study samples that are much larger than can
be generated from single-center cohorts.13 ACS NSQIP
collects information on several variables indicating that
a patient has advanced malignant disease (eg, the pres-
ence of disseminated cancer or recent chemoradiation)
even if cancer is not listed as the principal operative
diagnosis. The objectives of our study were therefore
to describe the early postoperative outcomes of patients
with advanced malignancy who underwent surgical
revascularization for arterial thromboembolic disease
of the lower extremities and to determine how the987
Table I. Patient- and procedure-related variables included as potential predictors of 30-day postoperative outcomes after
surgical revascularization for lower extremity arterial thromboembolism
Variable Components (if composite variable)
Age N/A
Gender N/A
Diabetes mellitus N/A
Ongoing tobacco use N/A
Chronic obstructive pulmonary disease N/A
Prior percutaneous coronary intervention and/or cardiac surgery N/A
End-stage renal disease N/A
History of transient ischemic attacks N/A
Prior cerebrovascular accident N/A
Chronic steroid use N/A
Preoperative mechanical ventilation N/A
Pneumonia N/A
Acute congestive heart failure N/A
Myocardial infarction within 6 months before operation N/A
Angina within 30 days before operation N/A
Acute renal failure N/A
SIRS/sepsis N/A
Prior lower extremity revascularization procedure N/A
Rest pain and/or extremity gangrene N/A
Nonindependent functional health status N/A
Physical disability Hemiplegia and/or paraplegia and/or quadriplegia
Cognitive disability Impaired sensorium and/or preoperative coma
Malnutrition Serum albumin level <3.2 g/dL and/or >10% weight loss in 6
months before operation and/or body mass index <20 kg/m2
Bleeding disorder N/A
ASA physical status classiﬁcation of 4 or 5 N/A
Emergency procedure status N/A
Nonclean incisional wound N/A
Procedure type Thrombectomy/embolectomy or thromboendarterectomy or
bypass graft or amputation
ASA, American Society of Anesthesiologists; N/A, not applicable; SIRS, systemic inﬂammatory response syndrome.
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METHODS
The NSQIP Participant User Files for 2005 to 2011
were used for this retrospective analysis, which included
all patients who had (1) a postoperative diagnosis of lower
extremity arterial thrombosis/embolism (International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁ-
cation code 444.22 as noted by the postoperative diagnosis
provided in the brief operative note, operative report, or
ﬁnal pathology report) and (2) a primary Current Proce-
dure Terminology code for lower extremity embolec-
tomy/thrombectomy, thromboendarterectomy, bypass
graft, or amputation. Patients were excluded from analysis
if they had an operation within 30 days before their index
revascularization procedure. Since this study utilized only
de-identiﬁed NSQIP data, it was exempt from Institutional
Review Board approval and patient consent was not
required.
The characteristics and postoperative outcomes of pa-
tients with known advanced malignancy were ﬁrst assessed.
Patients were classiﬁed as having advanced malignancy if
they met one or more of the following criteria: (1) evidence
of disseminated cancer, (2) chemotherapy within the
30 days preceding index operation, (3) radiotherapy withinthe 90 days preceding index operation, or (4) presence of a
tumor of the central nervous system. ACS NSQIP deﬁnes
disseminated cancer for patients who have “cancer that:
(1) has spread to one site or more sites in addition to the
primary site and (2) in whom the presence of multiple me-
tastases indicates the cancer is widespread, fulminant, or
near terminal.” Chemotherapy is deﬁned as “any chemo-
therapy for cancer in the 30 days prior to surgery. Patient
is not included if treatment consists solely of hormonal
therapy.” Radiotherapy is deﬁned as “any radiotherapy
treatment for cancer in the 90 days prior to surgery,” and
tumor of the central nervous system is deﬁned as “a
space-occupying tumor of the brain or spinal cord, which
may be benign or secondary malignancies.”14 Patients
without any of these characteristics were classiﬁed as not
having advanced malignancy. The primary predictor vari-
able for our analysis was advanced malignancy. Other pa-
tient- and procedure-related variables that were assessed
are shown in Table I. Patients with missing data for serum
albumin level were assumed to have a normal level
(>3.2 g/dL). Bleeding disorder as deﬁned by ACS NSQIP
includes patients in whom anticoagulation therapy was not
stopped before their index operation. Systemic inﬂamma-
tory response syndrome (SIRS)/sepsis is deﬁned as the
presence of SIRS or sepsis. ACS NSQIP deﬁnes SIRS as
“the presence of two or more of the following within the
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degrees C, (2) heart rate >90 beats per minute, (3) respi-
ratory rate >20 breaths/minute or PaCO2 <32 mm Hg,
(4) white blood cell count >12,000 cells/mm3
or <4000 cells/mm3 or >10% immature (band) forms, or
(5) anion gap acidosis.” Sepsis is deﬁned as “SIRS and either
(1) positive blood culture or clinical documentation of pu-
rulence or positive culture from any site for which there is
documentation noting the site as the acute cause of sepsis
or (2) suspected preoperative clinical condition of infection,
or bowel infarction, which leads to the surgical procedure.”
Rest pain/gangrene is deﬁned by ACS NSQIP as follows:
“Rest pain is a more severe form of ischemic pain due to
occlusive disease, which occurs at rest and is often mani-
fested as a severe, unrelenting pain aggravated by elevation.
Gangrene is a marked skin discoloration and disruption
indicative of death and decay of tissues in the extremities
due to severe and prolonged ischemia.” Procedure type clas-
siﬁcation was based on the primary Current Procedure Ter-
minology code associated with each patient’s operation.
Postoperative outcomes that were assessed included
the rates of 30-day postoperative mortality and overall
30-day postoperative morbidity. Speciﬁc complications
that were assessed in our analysis of aggregate morbidity
included superﬁcial surgical site infection, deep incisional
surgical site infection, organ/space surgical site infection,
wound dehiscence, pulmonary embolism, pneumonia, un-
planned reintubation, mechanical ventilation >48 hours,
stroke, coma >24 hours, progressive renal insufﬁciency,
renal failure requiring dialysis, cardiac arrest requiring car-
diopulmonary resuscitation, myocardial infarction, deep
venous thrombosis, major bleeding (requiring ﬁve units
or more of packed red blood cells within 72 hours postop-
eratively), systemic sepsis, septic shock, peripheral nerve
injury, and urinary tract infection.
Patient- and procedure-related characteristics of pa-
tients with and without advanced malignancy were
compared with Pearson c2 tests for categorical variables
and Wilcoxon rank sum tests for continuous variables. To
determine the independent association between known
advanced malignancy and primary postoperative outcomes,
we next developed a multivariate logistic regression model
in which each primary outcome served as a dependent var-
iable. For each model, all patient- and procedure-related
variables that maintained a univariate association with the
outcome of interest at the P < .05 level were included as
potential predictor variables. Because the presence of
advanced malignancy was our primary predictor of interest,
this variable was forced into each model regardless of the
strength of its univariate association with postoperative
outcomes. The C statistic and Hosmer-Lemeshow statistic
were reported for both of these models. All statistical
analyses were performed with Stata Version 11.0 (College
Station, Tex).
RESULTS
A total of 136 patients with advanced malignancy who
underwent surgical revascularization for lower extremityarterial thromboembolism were included for analysis. Of
these patients, 84 (61.8%) had disseminated cancer per
the ACS NSQIP deﬁnition, 67 (49.3%) had chemotherapy
within 30 days of operation, 31 (22.8%) had radiotherapy
within 90 days of operation, and eight (5.9%) had a tumor
of the central nervous system. The preoperative and oper-
ative characteristics of these patients are shown in Table II
and are compared with those of 4195 patients from the
ACS NSQIP database who met the inclusion and exclusion
criteria of our study but who did not have advanced malig-
nancy. Compared with patients without advanced malig-
nancy, those with advanced malignancy were less likely to
have undergone prior intervention for coronary artery dis-
ease, more likely to present with SIRS or sepsis, and signif-
icantly less likely to have undergone a prior lower extremity
revascularization procedure (Table I). Patients with
advanced malignancy were also signiﬁcantly more likely
to demonstrate cognitive dysfunction or evidence of
malnutrition compared with patients without and to un-
dergo emergency surgical intervention. Finally, patients
with advanced malignancy were relatively more likely to
undergo thrombectomy/embolectomy and less likely to
undergo bypass grafting compared with patients without
advanced malignancy.
The 30-day postoperative outcomes of patients with
and without advanced malignancy are shown in
Table III. The mortality rate was 30.2% for patients
with advanced malignancy compared with 6.9% for pa-
tients without advanced malignancy. The odds of mortal-
ity after surgical revascularization for patients with
advanced malignancy, after adjustment for other potential
predictors of this outcome, was 5.92 (95% conﬁdence in-
terval, 3.69-9.52; P < .001). The overall 30-day postop-
erative morbidity rate was 38.2% in patients with
advanced malignancy and 28.3% in patients without
advanced malignancy. This difference was not statistically
signiﬁcant (adjusted odds ratio of morbidity in patients
with advanced malignancy, 1.28; 95% conﬁdence interval,
0.87-1.87; P ¼ .21). The C statistics for the multivariate
logistic regression models for mortality and morbidity
were 0.8744 and 0.6793, respectively. The Hosmer-
Lemeshow statistics for the mortality and morbidity
models were 7.38 (P ¼ .4963) and 5.80 (P ¼ .6695),
respectively.
Table IV shows the 30-day mortality rates after surgi-
cal revascularization for lower extremity arterial thrombo-
embolism, stratiﬁed both by emergency vs nonemergency
procedure status and by the presence or absence of
advanced malignancy. Univariate comparison of postoper-
ative mortality rates in patients undergoing nonemer-
gency procedures revealed signiﬁcant differences
between patients with and without advanced malignancy
in postoperative mortality for thromboembolectomy but
not for thromboendarterectomy or bypass grafting. Uni-
variate comparison of mortality in patients undergoing
emergency procedures revealed signiﬁcant differences
between patients with and without advanced malignancy
for all three procedures. Emergency procedures of any
Table II. Patient- and procedure-related characteristics of patients undergoing surgical revascularization for lower
extremity arterial thromboembolism, stratiﬁed by presence or absence of advanced malignancy
Characteristic
Advanced malignancy
(n ¼ 136), No. (%)
No advanced malignancy
(n ¼ 4195), No. (%) P value
Median age, years (IQR) 66 (57-76.5) 69 (58-81) .009
Female 59 (43.4) 1936 (46.2) .52
Diabetes mellitus 28 (20.6) 1102 (26.3) .14
Ongoing tobacco use 57 (41.9) 1582 (37.7) .32
Chronic obstructive pulmonary disease 20 (14.7) 503 (12.0) .34
Prior percutaneous coronary intervention and/or cardiac surgery 19 (14.0) 1241 (29.6) <.001
End-stage renal disease 1 (0.7) 126 (3.0) .12
History of transient ischemic attacks 9 (6.6) 316 (7.5) .69
Prior cerebrovascular accident 19 (14.0) 735 (17.5) .28
Chronic steroid use 9 (6.6) 187 (4.5) .23
Preoperative mechanical ventilation 7 (5.2) 105 (2.5) .06
Pneumonia 5 (3.7) 60 (1.4) .03
Acute congestive heart failure 6 (4.4) 247 (5.9) .47
Myocardial infarction in past 6 months 7 (5.2) 177 (4.2) .60
Angina in past 30 days 3 (2.2) 161 (3.8) .33
Acute renal failure 4 (2.9) 72 (1.7) .28
Preoperative SIRS or sepsis 47 (34.6) 584 (13.9) <.001
Prior lower extremity revascularization 22 (16.2) 1228 (29.3) .001
Rest pain/gangrene 37 (27.2) 1406 (33.5) .12
Nonindependent functional status 46 (33.8) 984 (23.5) .005
Physical disability 8 (5.9) 198 (4.7) .53
Cognitive disability 10 (7.4) 117 (2.8) .002
Malnutrition 63 (46.3) 873 (20.8) <.001
Bleeding disorder 61 (44.9) 1646 (39.2) .19
Nonclean incisional wound 3 (2.2) 136 (3.2) .50
ASA class $ 4 60 (44.1) 1216 (29.0) <.001
Emergency procedure 87 (64.0) 2003 (47.8) <.001
Procedure type
Thrombectomy/embolectomy 88 (64.7) 1931 (46.0) <.001
Thromboendarterectomy 26 (19.1) 822 (19.6)
Bypass graft 22 (16.2) 1442 (34.4)
ASA, American Society of Anesthesiologists; IQR, interquartile range; SIRS, systemic inﬂammatory response syndrome.
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with mortality rates of 29% or higher.
DISCUSSION
In this study, we describe the outcomes for 136 pa-
tients with advanced malignancy who underwent surgical
revascularization for lower extremity arterial thromboem-
bolic disease. The 30-day postoperative mortality rate for
this cohort was 30.2%, whereas the overall incidence of
postoperative morbidity was 38.2%. Stratiﬁed by emer-
gency procedure status, 18% of patients with advanced
malignancy who underwent nonemergency revasculariza-
tion and 37% of patients who underwent emergency revas-
cularization died within 30 days of operation. The presence
of advanced malignancy was associated with an approxi-
mately sixfold increase in the odds of postoperative death
after adjustment for patient- and procedure-related factors
but was not associated with a signiﬁcant increase in the
incidence of postoperative morbidity.
Our analysis is the largest description to date of the
outcomes of patients with advanced malignancy who un-
dergo surgical revascularization for lower extremity arterial
thromboembolism. The next largest study, published by El
Sakka et al4 in 2005, included 22 patients with cancer whowere evaluated for critical limb ischemia at a tertiary
vascular surgery unit. Eleven of these patients received sur-
gical intervention (thromboembolectomy in four, angio-
plasty in four, thrombolysis and angioplasty in two, and
surgical bypass in one); the remaining 11 patients were
managed with systemic anticoagulation alone. Although
the postoperative outcomes of the surgical patients were
not described, the authors of that study did conclude
that major surgical reconstruction in this patient popula-
tion is generally contraindicated because of a poor life ex-
pectancy (the 6-month survival was 50% in their cohort)
and the possibility that bypass graft patency would be nega-
tively affected by the hypercoagulable state associated with
malignancy.4 Javid et al7 also reviewed their center’s expe-
rience with management of extremity arterial ischemia in
20 patients with malignancy. Of the eight patients who
received operative management, ﬁve patients underwent
thromboembolectomy (bilateral in one patient) and three
patients underwent bypass grafting. Five of the six throm-
boembolectomy procedures were noted to have failed (four
of them within 24 hours), whereas two of the three grafts
failed. Overall 3-month and 1-year survival rates for this
cohort were 50% and 17%, leading the authors to conclude
that arterial thrombosis in cancer patients should be
Table IV. 30-Day postoperative outcomes of patients undergoing surgical revascularization for lower extremity arterial
thromboembolism, stratiﬁed by emergency procedure status and presence or absence of known cancer
Procedure type
Nonemergency procedures Emergency procedures
Cancer (n ¼ 49),
No. (%)
No cancer (n ¼ 2192),
No. (%)
Cancer (n ¼ 87),
No. (%)
No cancer (n ¼ 2003),
No. (%)
Thromboembolectomy 8/23 (35) 21/589 (3.6)a 19/65 (29.2) 162/1,342 (12.1)a
Thromboendarterectomy 1/14 (7) 13/456 (2.9)c 5/12 (42) 44/366 (12.0)b
Bypass graft 0/12 (0) 29/1147 (2.5)c 8/10 (80) 20/295 (6.8)a
All procedures 9/49 (18) 63/2192 (2.9)a 32/87 (37) 226/2,003 (11.3)a
aP < .001 in comparing procedure-speciﬁc outcome of cancer vs no cancer group.
bP <.01 in comparing procedure-speciﬁc outcome of cancer vs no cancer group.
cP ¼ not signiﬁcant in comparing procedure-speciﬁc outcome of cancer vs no cancer group.
Table III. 30-Day outcomes of patients undergoing surgical revascularization for lower extremity arterial
thromboembolism, stratiﬁed by presence or absence of advanced malignancy
Outcome
Advanced
malignancy
(n ¼ 136),
No. (%)
No advanced
malignancy
(n ¼ 4195),
No. (%)
P value
(univariate association)
Adjusted odds ratio (95% conﬁdence
interval) of outcome if advanced
malignancy; P value
30-day postoperative mortality 41 (30.2) 289 (6.9) <.001 5.92a (3.69-9.52); P < .001
30-day postoperative morbidity 52 (38.2) 1187 (28.3) .01 1.28b (0.87-1.87); P ¼ .21
aAdjustment for variables that have univariate association with 30-day mortality at P < .05 level (age, gender, ongoing tobacco use, chronic obstructive
pulmonary disease, end-stage renal disease, prior transient ischemic attack, prior stroke, chronic steroid use, preoperative ventilation, pneumonia, acute
congestive heart failure, myocardial infarction within past 6 months, acute renal failure, preoperative systemic inﬂammatory response syndrome/sepsis, prior
lower extremity revascularization, nonindependent functional health status, physical disability, cognitive disability, malnutrition, bleeding disorder, American
Society of Anesthesiologists physical status classiﬁcation of 4 or 5, emergency procedure status, and procedure type).
bAdjustment for variables that have univariate association with 30-day morbidity at P < .05 level (gender, diabetes mellitus, ongoing tobacco use, chronic
obstructive pulmonary disease, prior percutaneous coronary intervention or cardiac surgery, end-stage renal disease, prior stroke, chronic steroid use, pre-
operative ventilation, pneumonia, acute congestive heart failure, myocardial infarction within past 6 months, angina within past 30 days, acute renal failure,
preoperative systemic inﬂammatory response syndrome/sepsis, rest pain and/or gangrene, nonindependent functional health status, physical disability,
cognitive disability, malnutrition, bleeding disorder, nonclean incisional wound classiﬁcation, American Society of Anesthesiologists physical status classiﬁ-
cation of 4 or 5, emergency procedure status, and procedure type).
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may be the most appropriate management. In only one
previous study do the authors advocate for aggressive sur-
gical management. In that study, Tsang et al9 reviewed the
results of 16 patients with cancer who underwent surgical
intervention for acute arterial ischemia at a university teach-
ing hospital. All patients underwent initial systemic intrave-
nous anticoagulation followed by thromboembolectomy,
with two of the 16 patients also receiving bypass grafting.
Of the cohort of 16 patients, six (including both of the pa-
tients who received bypass grafts) required subsequent
amputation for deteriorating limb condition. The inpatient
mortality rate for the cohort was 12%, and the overall sur-
vival at 1 year was 44%, leading the authors to conclude
that surgical revascularization is an acceptable treatment
option for cancer patients who develop acute limb
ischemia.
The results of our study suggest that patients with
advanced malignancy who undergo emergency surgical
revascularization for lower extremity arterial thromboem-
bolism have an exceedingly high incidence of early postop-
erative mortality. Whether acute limb ischemia in such
patients should indeed be considered a preterminal event,and thus managed primarily with medical palliation, greatly
depends on the treatment goals of the individual patient.
Whereas concern for long- or medium-term limb salvage
is probably moot for most of these patients because of their
limited life expectancies, short-term limb salvage may be
important enough to them that they may opt to accept
the risks of death or failure pursuant to attempted revascu-
larization. Alternatively, other patients may prioritize the
alleviation of ischemia-induced pain over limb salvage.
Medical palliation with narcotics, neuropathic agents, or
other types of medications may reasonably be attempted
in such patients.15,16 If this fails to provide effective symp-
tom control, amputation may serve as a less aggressive sur-
gical alternative to revascularization. Regardless of which
treatment option is ultimately chosen, surgeons should
ensure that patients have a realistic expectation of the antic-
ipated outcomes of surgical revascularization and be delib-
erate in their solicitation of patients’ overall goals of care.
Our study has several important limitations. First,
because ACS NSQIP contains information only about
those patients who received an operation, we were not
able to determine the outcomes of cancer patients in
whom critical limb ischemia was managed without surgery.
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the relative efﬁcacies of surgical revascularization, amputa-
tion, or medical management alone for limb ischemia in the
setting of advanced malignancy. Second, we do not include
information about the anatomic location of arterial occlu-
sion, the acuity or severity of the resulting ischemia, or
the presence or extent of underlying atherosclerotic periph-
eral arterial disease for each patient. We therefore do not
know the speciﬁc rationale for each procedure that was per-
formed in our patient cohort and therefore do not know
the speciﬁc rationales for the procedures that were per-
formed in our patient cohort. Speciﬁcally, even though
our analysis includes only patients who received a postoper-
ative diagnosis of arterial thromboembolism, the fact that
some patients underwent thromboendarterectomy or
bypass grafting indicates that the presence of pre-existing
atherosclerotic disease may have contributed to the poor
outcomes of these patients. In addition, it is possible that
patients undergoing nonemergency thromboendarterec-
tomy or bypass grafting may not have suffered acute limb
ischemia because more than thromboembolectomy was
performed and the patients did not require emergency oper-
ation. Third, several factors could not be included as poten-
tial predictor variables in our analysis but may potentially
affect the outcomes of cancer patients who receive surgical
intervention for arterial thromboembolism (including the
type and stage of cancer, preoperative blood product trans-
fusion, and use of heparin). Fourth, our cohort includes only
those patients with evidence of advanced malignancy. We do
not know the primary source of cancer in these patients, the
duration or exact extent of their oncologic disease, or
whether similar outcomes might be expected in patients
with early-stage cancer who undergo operation for critical
limb ischemia. As a result of this limitation, any conclusions
drawn from our study must necessarily apply only to those
patients with advanced malignancy and not to patients
with earlier stages of cancer who may have longer life
expectancies.
CONCLUSIONS
Despite its limitations, our analysis is the largest to date
to describe the early postoperative outcomes of patients
with advanced malignancy who undergo surgical revascu-
larization for lower extremity arterial thromboembolism.
Although management decisions in such patients must by
necessity be individualized, the results of our study suggest
that early outcomes after emergency revascularization at-
tempts are extremely poor. Palliative care consultation
should routinely be obtained in such patients to assist the
vascular surgeon in soliciting treatment goals. For those pa-
tients in whom alleviation of pain preempts short-term limb
salvage as the primary goal of care, medical symptom man-
agement or amputation may represent less aggressive but
potentially effective treatment modalities.AUTHOR CONTRIBUTIONS
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